Close Menu

NEW YORK — Yourgene Health said on Friday that it has received approval to sell its Elucigene DPYD chemotoxicity diagnostic assay in Australia.

The genotyping test, which was launched last year, is designed to identify cancer patients with dihydropyrimidine dehydrogenase deficiency, which can result in life-threatening side effects when the patients are treated with the chemotherapeutic agent 5-fluorouracil. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.